DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo

Resistance to VEGF inhibitors is emerging as a major clinical problem. Notch signaling has been implicated in tumor angiogenesis. Therefore, to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced human glioblastoma cells with retroviruses encoding Notch delta-like ligand 4...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Jg. 71; H. 18; S. 6073
Hauptverfasser: Li, Ji-Liang, Sainson, Richard C A, Oon, Chern Ein, Turley, Helen, Leek, Russell, Sheldon, Helen, Bridges, Esther, Shi, Wen, Snell, Cameron, Bowden, Emma T, Wu, Herren, Chowdhury, Partha S, Russell, Angela J, Montgomery, Craig P, Poulsom, Richard, Harris, Adrian L
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 15.09.2011
Schlagworte:
Angiogenesis Inhibitors - pharmacology
Animals
Antibodies, Monoclonal, Humanized - pharmacology
Bevacizumab
Cell Hypoxia - physiology
Cell Line, Tumor
Dibenzazepines - pharmacology
Drug Resistance, Neoplasm
Female
Fibrosarcoma - blood supply
Fibrosarcoma - drug therapy
Fibrosarcoma - metabolism
Glioblastoma - blood supply
Glioblastoma - drug therapy
Glioblastoma - metabolism
Humans
Intracellular Signaling Peptides and Proteins - metabolism
Membrane Proteins - metabolism
Mice
Mice, Inbred BALB C
Mice, SCID
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - pathology
Receptors, Notch - metabolism
Signal Transduction
Transplantation, Heterologous
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - biosynthesis
ISSN:1538-7445, 1538-7445
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Resistance to VEGF inhibitors is emerging as a major clinical problem. Notch signaling has been implicated in tumor angiogenesis. Therefore, to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced human glioblastoma cells with retroviruses encoding Notch delta-like ligand 4 (DLL4), grew them as tumor xenografts and then treated the murine hosts with the VEGF-A inhibitor bevacizumab. We found that DLL4-mediated tumor resistance to bevacizumab in vivo. The large vessels induced by DLL4-Notch signaling increased tumor blood supply and were insensitive to bevacizumab. However, blockade of Notch signaling by dibenzazepine, a γ-secretase inhibitor, disrupted the large vessels and abolished the tumor resistance. Multiple molecular mechanisms of resistance were shown, including decreased levels of hypoxia-induced VEGF and increased levels of the VEGF receptor VEGFR1 in the tumor stroma, decreased levels of VEGFR2 in large blood vessels, and reduced levels of VEGFR3 overall. DLL4-expressing tumors were also resistant to a VEGFR targeting multikinase inhibitor. We also observed activation of other pathways of tumor resistance driven by DLL4-Notch signaling, including the FGF2-FGFR and EphB4-EprinB2 pathways, the inhibition of which reversed tumor resistance partially. Taken together, our findings show the importance of classifying mechanisms involved in angiogenesis in tumors, and how combination therapy to block DLL4-Notch signaling may enhance the efficacy of VEGF inhibitors, particularly in DLL4-upregulated tumors, and thus provide a rational base for the development of novel strategies to overcome antiangiogenic resistance in the clinic.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1538-7445
1538-7445
DOI:10.1158/0008-5472.CAN-11-1704